Trial Profile
A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Anal cancer; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Calithera Biosciences; Takeda Oncology
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 02 Feb 2019 Planned End Date changed from 30 Jan 2019 to 28 Feb 2019.
- 21 Jan 2019 Planned End Date changed from 21 Dec 2018 to 30 Jan 2019.